Gilead inks deal with Canadian antibody discovery firm AbCellera
pharmafile | June 14, 2019 | News story | Medical Communications | AbCellera, Gilead, monoclonal antibodies, pharma
Gilead has entered into an agreement with Canadian monoclonal antibody discovery firm AbCellera.
The two firms will take part in a cross border collaboration to support the discovery of new therapeutic antibody candidates for infectious diseases.
Under the terms of the agreement AbCellera will receive upfront and research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.
“AbCellera is dedicated to partnering with the most innovative companies to discover breakthrough therapies, and we look forward to adding our technology to Gilead’s early research efforts,” commented Carl Hansen, President and CEO of AbCellera.
Using a sutie of proprietary technologies, AbCellera will be looking for ultra-rare antibodies with specific properties defined by Gilead.
Louis Goss
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …